LCZ696在慢性心力衰竭治疗中的研究进展
摘要
心力衰竭称为＂心血管疾病中的新型流行病＂,被认为是新世纪的主要课题,已成为世界上影响公众健康的主要疾病。从19世纪80年代开始,心力衰竭的治疗模式出现了多次转变。
出处
《医疗装备》
2016年第11期201-202,共2页
Medical Equipment
参考文献5
-
1刘婷婷,葛漫丽,王继红,李庆伟,刘欣.中性肽链内切酶(CD10)生理功能研究进展[J].现代生物医学进展,2014,14(9):1766-1768. 被引量：3
-
2李能刚,徐进宜,吴晓明.血管紧张素转化酶和中性肽链内切酶的双重抑制剂[J].药学进展,2000,24(3):133-136. 被引量：4
-
3Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial[J]. Lancet, 2012, 380(9851):1387-1395.
-
4McMurray J J, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failu~[J]. N Engl J Med, 2014, 371(11):993-1004.
-
5Vodovar N, Paquet C, Mebazss A, et al. Neprilysin, cardiovascular, and Alzheimer' s disease: the therapeutic spilt?[J]. Eur Heart J, 2015, 36(15):902-905.
二级参考文献22
-
1Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border [J] Biochem J, 1974, 137:477.
-
2Greaves MF, Hairi G, Newman RA et al. Selective expression of the common acute lymphoblasic leukemia(gp100) antigen on immature l- ymphoid cells and their malignant counterparts [J]. Blood, 1983, 61 : 628.
-
3Sexton T, Hitchcook LJ, Rodgers DW, et al. Active site mutations change the cleavage specificity ofneprilysin [J]. PLoS One, 2012,7(2): e32343.
-
4Kalled SL, Siva N, Stein H, et al. The distribution of CDIO (NEP 24.11, CALLA) in humans and mice is similar in non-lymphoid organs but differs within the hematopoietic system: absence on murine T and B lymphoid progenitors [J] Eur J Immunol, 1995, 25(3):677-687.
-
5Maguer-Satta V, Besan on R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD 10): a multifaceted environment actor in st- em cells, physiological mechanisms, and cancer [J]. Stem Cells, 2011 29(3):389-396.
-
6Kontargiris E, Vadalouka A, Ragos V, et al. Zinc Inhibits Apoptosis and Maintains NEP Downregulation, Induced by Ropivacaine, in HaCaT Cells [J]. Biol Trace Elem Res, 2012, 150(1-3):460-466.
-
7Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key [J]. Blood, 1993, 82 (4): 1052-1070.
-
8Beaumont A, Le Moual H, Boileau G, et al. Evidence that both arginine 102 and arginine 747 are involved in substrate binding to neutral endopeptidase (EC 3.4.24.11) [J]. J Biol Chem, 1991, 266(1): 214-220.
-
9Greco S J, Corcoran KE, Cho C J, et al. Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and mainten- ance ofhematopoietic stem cells [J]. Front Biosci, 2004, 9:1782-1793.
-
10Adamus M. Substance P as a regulatory peptide of hematopoiesis and blood cell functions [J]. Postepy Hig Med Dosw, 2009, 63:106-113.
共引文献5
-
1张小平.血管紧张素转换酶抑制剂和血管肽酶抑制剂研究进展[J].食品与药品,2006,8(03A):15-18. 被引量：2
-
2胡玉琼,李家富.BNP在心力衰竭中的研究进展[J].深圳中西医结合杂志,2015,25(2):193-194.
-
3牛福勇,李福荣.肝细胞癌中性肽链内切酶和二肽基肽酶Ⅳ表达水平对手术切除术后患者预后的影响[J].实用肝脏病杂志,2017,20(5):559-562.
-
4陈敬祥,程杰,林同.松墨天牛中性肽链内切酶2基因的鉴定与表达[J].西北农业学报,2017,26(8):1239-1247.
-
5王瑶,陶则伟,陆贤,黄元伟.B型钠尿肽的研究进展[J].心脏杂志,2003,15(6):555-557. 被引量：41
-
1刘萧,洪葵.心力衰竭治疗的新策略：血管紧张素受体脑啡肽酶双重抑制剂[J].中华心血管病杂志,2015,43(12):1025-1027. 被引量：4
-
2赵静,李法琦.新药LCZ696在心血管疾病中的研究进展[J].现代医药卫生,2015,31(10):1477-1480.
-
3钱方毅.治疗心力衰竭新药:血管紧张素受体拮抗剂及脑啡肽酶双重抑制剂LCZ696[J].中华老年多器官疾病杂志,2016,15(7):553-557. 被引量：6
-
4谭漪扬,周建中.慢性心力衰竭治疗新进展——LCZ696![J].心血管病学进展,2016,37(1):42-45. 被引量：8
-
5周沛宁,苏欣,赵水平.LCZ696治疗心衰的研究进展[J].医学临床研究,2015,32(6):1188-1189. 被引量：1
-
6王宏亮,王欢.首个血管紧张素受体-脑啡肽酶双重抑制剂—Entresto(sacubitril/缬沙坦)[J].临床药物治疗杂志,2015,13(6):85-88. 被引量：7
-
7李文鹏,赵虹.新型降压药物LCZ696挑战传统心力衰竭治疗[J].中国循环杂志,2016,31(7):723-725. 被引量：2
-
8王辉波,杨俊,彭娟.LCZ696在慢性心力衰竭中的研究进展[J].临床心血管病杂志,2015,31(5):468-470. 被引量：4
-
9杨永健.心力衰竭治疗进展述评[J].西部医学,2016,28(3):297-299. 被引量：28
-
10黄震华.兼有血管紧张肽转换酶抑制作用和脑啡肽酶抑制作用的药物在心血管疾病治疗中的应用[J].中国新药与临床杂志,2008,27(8):608-611.
